Targeted Oncology· @TargetedOnc · X·· 1 day agoScore70
Body · original
A fascinating VOLGA finding:
EV + durvalumab improved EFS and OS, while adding tremelimumab improved EFS but did not meet OS significance.
Do we really need CTLA-4 intensification?
More treatment isn’t necessarily better. Toxicity and absolute benefit matter. #ESMO26
77 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com